Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic cells in patients with advanced or recurrent epithelial ovarian cancer
Epistemonikos ID: 105768c421505d5e24dba5429e3f52183224b02c
First added on: May 07, 2024